291 related articles for article (PubMed ID: 23245394)
1. Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry.
Puymirat E; Cohen S; Védrenne G; Caruba T; Sabatier B; Danchin N; Durand E
Ann Cardiol Angeiol (Paris); 2013 Apr; 62(2):89-94. PubMed ID: 23245394
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
[TBL] [Abstract][Full Text] [Related]
4. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and economical evaluation of bivalirudin during percutaneous coronary interventions].
Caruba T; Chaïb A; Danchin N; Rahal S; Bégué D; Durand E; Prognon P; Lafont A; Sabatier B
Ann Cardiol Angeiol (Paris); 2010 Apr; 59(2):72-8. PubMed ID: 19962685
[TBL] [Abstract][Full Text] [Related]
7. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin: a pharmacoeconomic profile of its use in patients with acute coronary syndromes.
Lyseng-Williamson KA
Pharmacoeconomics; 2011 Apr; 29(4):343-59. PubMed ID: 21395353
[TBL] [Abstract][Full Text] [Related]
11. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Mishkel GJ; Moore AL; Markwell SJ; Ligon RW
J Invasive Cardiol; 2007 Feb; 19(2):63-8. PubMed ID: 17268039
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
Summers KM; Holdford DA; Crouch MA
Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention.
Huston SA; Hawkins D
Curr Pharm Des; 2008; 14(12):1197-204. PubMed ID: 18473867
[TBL] [Abstract][Full Text] [Related]
20. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
